Clinical Trials Browser

NIH × pertuzumab × Gynecologic × Clear all

NCT05256225 2026-03-19

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms